UBS Group
FHTX icon

UBS Group’s Foghorn Therapeutics FHTX Stock Holding History

UBS Group’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$362K Buy
75,835
+51,330
+209% +$282K ﹤0.01% 6301
2025
Q4 		$132K Sell
24,505
-10,339
-30% -$46.9K ﹤0.01% 6770
2025
Q3 		$170K Sell
34,844
-7,956
-19% -$42.2K ﹤0.01% 6767
2025
Q2 		$201K Sell
42,800
-3,558
-8% -$14.9K ﹤0.01% 6718
2025
Q1 		$169K Buy
46,358
+8,863
+24% +$40.4K ﹤0.01% 6653
2024
Q4 		$177K Buy
37,495
+25,565
+214% +$186K ﹤0.01% 6527
2024
Q3 		$111K Buy
11,930
+4,239
+55% +$30.7K ﹤0.01% 6279
2024
Q2 		$44.2K Sell
7,691
-12,683
-62% -$75.5K ﹤0.01% 6783
2024
Q1 		$137K Sell
20,374
-3,007
-13% -$16.7K ﹤0.01% 6082
2023
Q4 		$151K Buy
23,381
+12,945
+124% +$55.8K ﹤0.01% 5946
2023
Q3 		$52.2K Sell
10,436
-1,895
-15% -$14.6K ﹤0.01% 6267
2023
Q2 		$86.8K Buy
12,331
+4,672
+61% +$32.7K ﹤0.01% 6125
2023
Q1 		$47.5K Buy
7,659
+2,612
+52% +$17.1K ﹤0.01% 6496
2022
Q4 		$32.2K Buy
+5,047
New +$38.1K ﹤0.01% 7165
2022
Q2 		– Sell
-2,923
Closed -$45K – 10496
2022
Q1 		$45K Sell
2,923
-3,970
-58% -$54.5K ﹤0.01% 6600
2021
Q4 		$158K Buy
+6,893
New +$99.1K ﹤0.01% 5895
2021
Q2 		– Sell
-2,136
Closed -$28K – 9495
2021
Q1 		$28K Sell
2,136
-112
-5% -$1.83K ﹤0.01% 7063
2020
Q4 		$46K Buy
+2,248
New +$43.1K ﹤0.01% 6258

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

UBS Group's FHTX Position: Q1 2026 in Review

UBS Group increased its Foghorn Therapeutics (FHTX) stake by 209% in Q1 2026, buying an estimated $282K and bringing the position to 75,835 shares worth $362K. The position accounts for ﹤0.01% of the portfolio, ranked #6301.

UBS Group first reported a position in FHTX in Q4 2020 and has held it in 18 quarters since. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • UBS Group held 75,835 shares of Foghorn Therapeutics worth $362K as of Q1 2026.
  • UBS Group bought 51,330 Foghorn Therapeutics shares in Q1 2026, an estimated $282K.
  • Foghorn Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6301 holding.
  • UBS Group first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 18 quarters since.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.